PCSK9 and Hypercholesterolemia: In the past decade, proprotein convertase subtilisin/kexin type 9 (PCSK9) emerged as a novel target for the treatment of hypercholesterolemia with the approval of 2 monoclonal antibodies, alirocumab and evolocumab (3).